Applied DNA Sciences, Inc. (NASDAQ:APDN) Short Interest Up 199.4% in December

Applied DNA Sciences, Inc. (NASDAQ:APDNGet Free Report) was the recipient of a large growth in short interest during the month of December. As of December 15th, there was short interest totalling 5,300,000 shares, a growth of 199.4% from the November 30th total of 1,770,000 shares. Based on an average daily volume of 5,810,000 shares, the days-to-cover ratio is presently 0.9 days.

Applied DNA Sciences Stock Up 0.7 %

Shares of Applied DNA Sciences stock traded up $0.00 during trading on Friday, reaching $0.18. 3,452,442 shares of the company were exchanged, compared to its average volume of 4,233,988. The business has a 50-day moving average price of $0.20 and a 200-day moving average price of $0.58. The firm has a market capitalization of $9.41 million, a price-to-earnings ratio of -0.02 and a beta of 0.46. Applied DNA Sciences has a twelve month low of $0.12 and a twelve month high of $14.40.

Applied DNA Sciences (NASDAQ:APDNGet Free Report) last posted its earnings results on Tuesday, December 17th. The technology company reported ($0.32) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.33) by $0.01. Applied DNA Sciences had a negative return on equity of 138.41% and a negative net margin of 214.42%. On average, equities research analysts forecast that Applied DNA Sciences will post -1.8 EPS for the current fiscal year.

Institutional Investors Weigh In On Applied DNA Sciences

An institutional investor recently bought a new position in Applied DNA Sciences stock. Jane Street Group LLC bought a new position in shares of Applied DNA Sciences, Inc. (NASDAQ:APDNFree Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 73,396 shares of the technology company’s stock, valued at approximately $48,000. Jane Street Group LLC owned approximately 0.24% of Applied DNA Sciences as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 22.22% of the company’s stock.

Analyst Ratings Changes

Separately, StockNews.com upgraded shares of Applied DNA Sciences to a “sell” rating in a report on Tuesday, September 17th.

View Our Latest Stock Report on APDN

Applied DNA Sciences Company Profile

(Get Free Report)

Applied DNA Sciences, Inc, a biotechnology company, develops and commercializes technologies to produce and detect deoxyribonucleic acid (DNA) in the Americas, Europe, Asia, and internationally. It operates through three segments: Therapeutic DNA Production Services; MDx Testing Services; and DNA Tagging and Security Products and Services.

Featured Articles

Receive News & Ratings for Applied DNA Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Applied DNA Sciences and related companies with MarketBeat.com's FREE daily email newsletter.